相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines Agency
Andrew S. Levey et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2020)
Microvascular and Cardiovascular Outcomes According to Renal Function in Patients Treated With Once-Weekly Exenatide: Insights From the EXSCEL Trial
M. Angelyn Bethel et al.
DIABETES CARE (2020)
Prediction and validation of exenatide risk marker effects on progression of renal disease: Insights from EXSCEL
Nienke M. A. Idzerda et al.
DIABETES OBESITY & METABOLISM (2020)
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
V. Perkovic et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
GFR Slope as a Surrogate End Point for Kidney Disease Progression in Clinical Trials: A Meta-Analysis of Treatment Effects of Randomized Controlled Trials
Lesley A. Inker et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2019)
Evaluating Glomerular Filtration Rate Slope as a Surrogate End Point for ESKD in Clinical Trials: An Individual Participant Meta-Analysis of Observational Data
Morgan E. Grams et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2019)
Effect of Canagliflozin on Renal and Cardiovascular Outcomes across Different Levels of Albuminuria: Data from the CANVAS Program
Brendon L. Neuen et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2019)
Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial
Ofri Mosenzon et al.
LANCET DIABETES & ENDOCRINOLOGY (2019)
Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial
Katherine R. Tuttle et al.
LANCET DIABETES & ENDOCRINOLOGY (2018)
GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes
Marcel H. A. Muskiet et al.
NATURE REVIEWS NEPHROLOGY (2017)
Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
Rury R. Holman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Liraglutide and Renal Outcomes in Type 2 Diabetes
Johannes F. E. Mann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
The potential and pitfalls of GLP-1 receptor agonists for renal protection in type 2 diabetes
Merlin C. Thomas
DIABETES & METABOLISM (2017)
Rationale and design of the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) trial
Rury R. Holman et al.
AMERICAN HEART JOURNAL (2016)
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Steven P. Marso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Steven P. Marso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Marc A. Pfeffer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Decline in Estimated Glomerular Filtration Rate and Subsequent Risk of End-Stage Renal Disease and Mortality
Josef Coresh et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)
分享论文
